Since dual PPARα and PPARγ agonists might provide broader beneficial metabolic effects through a simultaneous treatment of hyperglycemia and dyslipidemia, compounds targeting both PPARα and γ have been developed by the pharmaceutical industry. The gene discussed is PPARG; the disease is Hyperglycemia.